Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Attention Deficit Hyperactivity Disorder
Strattera now more widely available in Europe
June 17th, 2005
Eli Lilly and Company's Strattera (atomoxetine HCl), the only approved non-stimulant medication proven clinically effective at treating the symptoms of attention deficit hyperactivity disorder (ADHD), is now more widely available in Europe, following marketing authorizations granted by regulatory authorities in Germany, The Netherlands and Norway. Strattera is approved for the treatment of ADHD in children and adolescents in these countries. A selective norepinephrine reuptake inhibitor, Strattera represents the first new class of ADHD medications in the 50 years since stimulant medications first began being used. Strattera became available in...
Source: Drug Week (2005-06-17)
|
